Fosun independent research and development of new drugs in clinical trials eligible for drug approval
Friday, July 08, 2016
Shanghai Fosun Pharmaceutical Co., Ltd. announcement called Star Thai subsidiary of Shanghai Pharmaceutical Co., Ltd., Guilin pharmaceutical Co., Ltd. received the State food and drug administration of the recently agreed on ex miscellaneous Lu amine soft capsules and drug grace miscellaneous Lu amine (hereinafter collectively referred to as "the drug") in this document clinical trials.
The new drug is Fosun Pharma and its subsidiaries independently developed the original 3.1 class of chemicals for metastatic castration-resistant prostate cancer. Announcements , currently in China (not including Hong Kong, Macao and Taiwan regions, the same below) has no listed ex miscellaneous Lu amine soft capsules. According to IMS MIDAS data (by the IMS Health provides, IMS Health is the world's leading pharmaceutical and healthcare industry intelligence and strategic consulting services), , 2015 Nian En miscellaneous Lu amine soft capsules in the global market sales of about 16.05 billion US dollars. Fosun said that at this stage in respect of new drugs has been put into research and development expenses of approximately RMB 810 million.
Fosun announcement also prompted the risks associated with drug development in accordance with relevant Chinese regulations, which still need to carry out a series of clinical studies of new drugs and drug evaluation by the State after approval by the department before listing.
Fosun always independent innovation as the source for enterprise development, continuous improvement "imitation and combination" Drug research and innovation system. In recent years, Fosun continue to increase investment in research and development, it has become an international research and development layout and strong R&D capability. Currently, Fosun Pharmaceutical R&D staff of nearly 900 people, through Shanghai, Chongqing, Taipei, San Francisco interactive layout establish an integrated research system, increasing investment in research and development of four major platforms, innovative drugs in small molecule chemistry, macromolecular similar field of biological medicine, high-value generics, specialty formulation technology to create a highly efficient R&D platform.
Source : fosunpharma.com
